The Pathophysiology of Benign Prostatic Hyperplasia
Overview
Urology
Authors
Affiliations
Although benign prostatic hyperplasia (BPH) is one of the most common disease processes affecting the aging male, surprisingly little is known about its pathophysiology. Cause-and-effect relationships have not been established, despite intense research efforts in the last four or five decades aimed at elucidating the underlying etiology of prostatic growth in older men. Previously held notions that the clinical symptoms of BPH (prostatism) are due simply to a mass-related increase in urethral resistance are too simplistic. It is now clear that a significant portion of the symptoms are due to obstruction-induced detrusor dysfunction. Moreover, obstruction may induce a variety of neural alterations in the bladder and prostate that contribute to symptomatology. Undoubtedly, the constellation of cellular pathologies that give rise to the symptoms of BPH will be far more complex than we currently realize. Only by unraveling these complexities, however, will we be able successfully to design alternative strategies to treat, and possibly prevent BPH.
Kumbukgahadeniya P, Baek E, Hong E, Song J, Kwak Y, Jang M Pharmaceuticals (Basel). 2024; 17(11).
PMID: 39598426 PMC: 11597678. DOI: 10.3390/ph17111516.
Current Understanding of Androgen Signaling in Prostatitis and its Treatment: A Review.
Cabeza M Curr Med Chem. 2024; 31(27):4249-4266.
PMID: 38243983 DOI: 10.2174/0109298673279207231228070533.
Role of prostate stem cells and treatment strategies in benign prostate hyperplasia.
Gangavarapu K, Jowdy P, Foster B, Huss W Am J Clin Exp Urol. 2022; 10(3):154-169.
PMID: 35874288 PMC: 9301063.
Zinc Deficiency in Men Over 50 and Its Implications in Prostate Disorders.
Sauer A, Vela H, Vela G, Stark P, Barrera-Juarez E, Grabrucker A Front Oncol. 2020; 10:1293.
PMID: 32850402 PMC: 7424038. DOI: 10.3389/fonc.2020.01293.
Chiang B, Kuo H, Liao C Toxins (Basel). 2019; 11(9).
PMID: 31546892 PMC: 6784075. DOI: 10.3390/toxins11090547.